Ionis Pharmaceuticals reported positive pivotal Phase 3 data demonstrating that its antisense oligonucleotide Olezarsen sharply reduces triglyceride levels by up to 72% and cuts acute pancreatitis events by 85% in patients with severe hypertriglyceridemia. The drug was generally well tolerated with safety consistent across groups. These results provide significant support for an expanded label, with filings planned. Market analysts have noted the drug’s potential in a broader hypertriglyceridemia population, anticipating substantial commercial opportunity beyond its current rare disease approval. This underscores expanding RNA therapeutics targeting cardiometabolic disease.